Preferences for Fractures and Other Glucocorticoid-Associated Adverse Effects among Rheumatoid Arthritis Patients

Objective. The objective of this study was to determine rheumatoid arthritis (RA) patients’ preferences for validated health state scenarios depicting glucocorticoid adverse events, predictors of these preferences, and psychometric properties of different preference techniques in this population. Methods. Preferences were elicited by rating scale and time trade-off methods. Time trade-offs included trading current health for either time spent alive in an adverse health state for chronic conditions (time trade-off) or time spent in a sleeplike state for acute conditions (sleep trade-off). Results. A total of 107 subjects with long-standing RA participated in the preference interviews. Mean preference values (rating scale/trade-off) were lowest for serious fracture adverse events, including hip fracture requiring a nursing home stay (0.55 ± 0.22/0.76 ± 0.36) and vertebral fracture with chronic pain (0.59 ± 0.23/0.67 ± 0.35), and highest for cataracts (0.84 ± 0.17/0.96 ± 0.09) and wrist fracture (0.82 ± 0.18/0.81 ± 0.29). Rating scales had a stronger correlation (r= 0.88) with physician ranking of scenarios than trade-off methods (r = 0.31). All methods were feasible and demonstrated good reliability, while rating scale method showed better construct validity than trade-off techniques. Conclusion. Relative to their current health, RA patients assigned low preference values to many glucocorticoid adverse events, particularly those associated with chronic fracture outcomes. Results varied with the preference measure used, indicating that methodological attributes of preference determinations must be considered in clinical decision making.

[1]  B. Jönsson,et al.  Economic consequences of the progression of rheumatoid arthritis in Sweden. , 1999, Arthritis and rheumatism.

[2]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[3]  K. Saag,et al.  Glucocorticoid-induced osteoporosis. , 2003, Endocrinology and metabolism clinics of North America.

[4]  Maureen,et al.  Methodological Issues of Patient Utility Measurement Experience From Two Clinical Trials , 1995, Medical care.

[5]  W Sumner,et al.  U-titer: a utility assessment tool. , 1991, Proceedings. Symposium on Computer Applications in Medical Care.

[6]  J. Hall,et al.  Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. , 1993, Journal of clinical epidemiology.

[7]  L. Cronbach.  Coefficient alpha and the internal structure of tests , 1951 .

[8]  R. Klein,et al.  The Beaver Dam Health Outcomes study , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  A. Newberg,et al.  Low dose prednisone therapy in rheumatoid arthritis: a double blind study. , 1983, The Journal of rheumatology.

[10]  S. Cummings,et al.  Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Status report , 1998 .

[11]  D. Furst,et al.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.

[12]  G. Bonsel,et al.  The comparability and reliability of five health-state valuation methods. , 1997, Social science & medicine.

[13]  C. Ashton,et al.  Assessing the performance of utility techniques in the absence of a gold standard. , 1999, Medical care.

[14]  Harold C. Sox,et al.  Variation in Patient Utilities for Outcomes of the Management of Chronic Stable Angina: Implications for Clinical Practice Guidelines , 1995 .

[15]  A. Hill,et al.  Small Doses of Prednisolone in the Management of Rheumatoid Arthritis , 1964, Annals of the rheumatic diseases.

[16]  G. Chapman,et al.  Prostate Cancer Patients' Utilities for Health States , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  M. Liang,et al.  Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. , 2003, Rheumatology.

[18]  M. Pringle,et al.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study , 1997 .

[19]  H. Fineberg,et al.  Preferences for Health Outcomes , 1984, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  N. Boyd,et al.  Eliciting Preferences for Alternative Cancer Drug Treatments , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  T. Pincus,et al.  Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. , 1992, The Journal of rheumatology.

[22]  S. van der Linden,et al.  Patient utilities in ankylosing spondylitis and the association with other outcome measures. , 1994, The Journal of rheumatology.

[23]  D. Glass,et al.  Single daily dose corticosteroid treatment. , 1976, Annals of the rheumatic diseases.

[24]  T. Spector,et al.  The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. , 1993, Arthritis and rheumatism.

[25]  J. Kenneth Buckingham,et al.  Comparing Three Versions of the Time Tradeoff , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  P. Dolan,et al.  The time trade-off method: results from a general population study. , 1996, Health economics.

[27]  George W. Torrance,et al.  Social preferences for health states: An empirical evaluation of three measurement techniques , 1976 .

[28]  S. Gabriel,et al.  Has the impact of hormone replacement therapy on health-related quality of life been undervalued? , 2000, Journal of women's health & gender-based medicine.

[29]  D. Furst,et al.  The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. , 1991, Seminars in arthritis and rheumatism.

[30]  D. Schwartz,et al.  Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. , 1996, Arthritis and rheumatism.

[31]  S. van der Linden,et al.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis , 1997, The Lancet.

[32]  W M O'Fallon,et al.  A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. , 1994, Arthritis and rheumatism.

[33]  J. Kellgren,et al.  LONG-TERM STUDY OF MANAGEMENT OF RHEUMATOID ARTHRITIS , 1984, The Lancet.

[34]  F. Wolfe,et al.  Measurement of the quality of life in rheumatic disorders using the EuroQol. , 1997, British journal of rheumatology.

[35]  P. V. van Riel,et al.  Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis , 1993, Annals of Internal Medicine.

[36]  L A Lenert,et al.  Effects on Preferences of Violations of Procedural Invariance , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[37]  J. Kirwan,et al.  The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. , 1995, The New England journal of medicine.

[38]  P. Hench,et al.  Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. , 1950, Archives of internal medicine.

[39]  P. Dolan,et al.  Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. , 1997, Social science & medicine.

[40]  W. Buchanan,et al.  Are 'homeopathic' doses of oral corticosteroids effective in rheumatoid arthritis? , 1988, Clinical and experimental rheumatology.

[41]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .

[42]  M. Johannesson,et al.  Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[43]  M K Goldstein,et al.  Measurement of the validity of utility elicitations performed by computerized interview. , 1997, Medical care.

[44]  J. Braun,et al.  Die glukokortikoidinduzierte Osteoporose , 2001, Der Orthopäde.

[45]  K. Saag.  Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. , 1997, The American journal of medicine.

[46]  Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[47]  J. Fries,et al.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. , 1982, The Journal of rheumatology.

[48]  Jackie Brown,et al.  Valuing temporary and chronic health states associated with breast screening. , 1998, Social science & medicine.

[49]  R Tibshirani,et al.  Describing Health States: Methodologic Issues in Obtaining Values for Health States , 1984, Medical care.

[50]  J. Sibley,et al.  Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. , 1994, The Journal of rheumatology.

[51]  F. Wolfe,et al.  Fractures in rheumatoid arthritis: an evaluation of associated risk factors. , 1993, The Journal of rheumatology.

[52]  A M Stiggelbout,et al.  The ‘Utility’ of the Visual Analog Scale in Medical Decision Making and Technology Assessment: Is It an Alternative to the Time Trade-off? , 1996, International Journal of Technology Assessment in Health Care.

[53]  B. McNeil,et al.  Decision analysis for public health: principles and illustrations. , 1984, Annual review of public health.

[54]  D. Pryor,et al.  Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. , 1995, JAMA.